Lovesac Co
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $LOVE in the last 30 days.
See all $LOVE insider activity →Cannara Biotech (LOVE) expanded its supply agreement with Curaleaf, increasing the potential value to C$34M over two years from C$21M. This is the company's first long-term international supply commitment.
Lovesac (LOVE) reported Q2 2027 net sales up 0.4% to $161.2M, net income of $7.4M, and adjusted EBITDA loss of $1.3M. Three analysts maintained Buy ratings but cut targets to $18-$20, citing soft demand and conservative guidance. High-end sales grew, but lower-end demand declined. Management guided Q3 sales to $140M-$150M with a net loss of $9M-$12M. Hedge fund ownership remained flat at 20 funds, with 21.93% short interest.
Canaccord cut Lovesac's (LOVE) price target to $20 but kept a Buy rating. Q2 revenue rose 0.4% YoY, with net income at $7.4M vs. a prior-year loss. Gross margin expanded to 68.4%, boosted by tariff refunds. The company lowered full-year sales and EBITDA guidance but raised net income outlook due to refunds. Analysts see 43.78% upside, with a median target of $20.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning LOVE (Lovesac Co). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent LOVE coverage spans earnings and financial news.
The contract expansion adds incremental revenue potential for Cannara Biotech.
Earnings beat on a one‑time tariff refund but underlying business loss; guidance lowered and analysts cut price targets.
Target reduction and weaker outlook may pressure the stock despite earnings beat.
Mixed impact: revenue beat but profit masked by one‑time refund; guidance suggests continued loss.
Positive earnings surprise and upgraded guidance may lift the stock; inventory buildup and tariff refund improve margins.
AlphAI scores every news story that mentions LOVE with an AI model for sentiment and relevance, and aggregates insider trades from Lovesac Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Cannara Biotech (LOVE) expanded its supply agreement with Curaleaf, increasing the potential value to C$34M over two years from C$21M. This is the company's first long-term international supply commitment.
1 min readLovesac (LOVE) reported Q2 2027 net sales up 0.4% to $161.2M, net income of $7.4M, and adjusted EBITDA loss of $1.3M. Three analysts maintained Buy ratings but cut targets to $18-$20, citing soft demand and conservative guidance. High-end sales grew, but lower-end demand declined. Management guided Q3 sales to $140M-$150M with a net loss of $9M-$12M. Hedge fund ownership remained flat at 20 funds, with 21.93% short interest.
2 min readCanaccord cut Lovesac's (LOVE) price target to $20 but kept a Buy rating. Q2 revenue rose 0.4% YoY, with net income at $7.4M vs. a prior-year loss. Gross margin expanded to 68.4%, boosted by tariff refunds. The company lowered full-year sales and EBITDA guidance but raised net income outlook due to refunds. Analysts see 43.78% upside, with a median target of $20.
2 min readLovesac (LOVE) reported record Q2 revenue of $161.2M, up 0.4%, driven by premium products and showroom sales. A $20M tariff refund boosted gross margin to 68.4%. However, core business lost $1.3M, with declines in lower-priced items and online sales. Management expects Q3 sales of $140M-$150M and a net loss of $9M-$12M.
2 min readThe Lovesac Company reported record Q2 2027 sales, with growth in premium products over $6,000. Management is shifting strategy to multi-platform offerings and onshoring production. Guidance reflects uncertainty in lower-priced segments. The company expects innovation-driven revenue in Q4, with flat SG&A. Financial adjustments include a $21M tariff refund and a 160 bps growth headwind from exiting Best Buy. Inventory increased to $130.2M for new launches.
3 min readLovesac (LOVE) reported Q2 CY2026 sales of $161.2M, flat year-over-year but in line with estimates. Next quarter's revenue guidance of $145M was 7.8% below expectations. EPS of $0.51 beat estimates, but the stock dropped 12.7%. Analysts expect 5.8% revenue growth over the next 12 months, with EPS projected to decline 68.2%.
2 min readLovesac (LOVE) reported Q2 net income of $7.4M ($0.51 per share), up from a loss last year, driven by IEEPA tariff refunds. Q3 loss guidance is $0.62-$0.83 per share on sales of $140M-$150M. FY27 EPS outlook raised to $0.98-$1.26, but sales forecast trimmed. Shares fell 12.7% pre-market.
2 min readLovesac Co (LOVE) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 THE LOVESAC COMPANY REPORTS SECOND QUARTER FISCAL 2027 FINANCIAL RESULTS Q2 Net Sales Increased to $161.2M Record Product Launches On Track for Second Half FY27 STAMFORD, Conn., September 10, 2026 (GLOBE NEWSWIRE) -- The Lovesac Company (Nasdaq: LOVE) (“Lovesac” or t
2 min readSeveral major companies, including Oracle, Adobe, and Copart, are set to report earnings on Thursday. Estimates for Oracle include EPS of $1.73 and revenue of $19.13B. Other companies reporting include Macy's, Restoration Hardware, and more, covering sectors like software, retail, and automotive services.
2 min readThe article summarizes Q1 results for Lovesac (LOVE), Mohawk Industries (MHK), Leggett & Platt (LEG), Purple (PRPL), and Somnigroup (SGI). It cites revenue and EPS/guidance beats or misses, plus post-report stock moves and current prices. It also provides a brief market-risk narrative shift from AI to geopolitics.
3 min read
